Tesofensine
Also known as: NS2330 · Tesofensine HCl
A serotonin-noradrenaline-dopamine reuptake inhibitor (SNDRI) originally developed for Parkinson and Alzheimer disease. In Phase 2 obesity trials, produced 12.8% weight loss over 6 months — more than twice that of approved weight loss drugs at the time.
Mechanism of Action
Tesofensine blocks the reuptake of all three monoamines (serotonin, norepinephrine, and dopamine) simultaneously. This triple reuptake inhibition reduces appetite, increases metabolic rate, and may improve mood. Unlike earlier diet drugs, it does not carry the same cardiovascular risks as amphetamines.
Benefits
- 12.8% weight loss in Phase 2 trials (6 months)
- Significantly reduces appetite and food intake
- Increases resting metabolic rate
- Triple monoamine reuptake inhibition (appetite center modulation)
- Potential for Alzheimer disease and Parkinson disease
- May improve mood and energy alongside weight loss
Side Effects & Risks
- Dry mouth (very common)
- Nausea and vomiting
- Constipation
- Insomnia
- Increased heart rate and blood pressure
- Not FDA-approved — research only
Where to Buy Tesofensine
2 options across 2 vendors · Sorted cheapest first · All include direct product link
From
$79.99
All links are affiliate links — PeptideWiki earns a commission at no extra cost to you. Coupon codes apply at checkout. Prices and availability may change. Always verify COA before purchasing.
Storage & Reconstitution Guide
Storage Temperature
-20°C (lyophilized)
24 months (lyophilized), 28 days (reconstituted)
Reconstitution Solvent
Bacteriostatic water (BAC water)
Swirl gently — do not shake or vortex
Handling Notes
Protect lyophilized peptide from moisture and light. Once reconstituted, keep refrigerated. Discard if solution becomes cloudy or discolored. Use insulin syringe for precise dosing.
Step-by-Step Reconstitution
Gather supplies
BAC water, insulin syringe, alcohol swabs, vial
Disinfect tops
Swab rubber stoppers of both vials with alcohol
Draw BAC water
Pull desired mL of BAC water into syringe
Inject slowly
Inject BAC water down the side of the peptide vial, swirl gently to dissolve
Clinical Trials & Human Studies1 trial
Efficacy of tesofensine for obesity in Phase 2 trial
Tesofensine produced 12.8% weight loss over 6 months versus 2.2% for placebo in Phase 2 obesity trial.
Research Protocol
- Dose Range
- 250–500 mcg
- Frequency
- Once daily oral
- Cycle
- 12-24 weeks
- Half-Life
- 220 hours (9 days)
- Routes
- oral
- Notes
- Phase 2 trials used 0.25-0.5mg/day. Start at 0.25mg to assess cardiovascular tolerance. Not approved for human use.
Legal & Regulatory Status
Sold for research purposes only. Not for human use. Laws vary by country.
Commonly Stacked With
View all peptide stacks →External Resources
More in Weight Management
5-Amino-1-methylquinolinium
A small molecule inhibitor of NNMT enzyme that boosts metabolism and promotes fat cell apoptosis. Shows promise as a novel anti-obesity agent in preclinical research.
LY3437943
An emerging triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 clinical trials show unprecedented weight loss of up to 24% body weight.
AOD9604
A synthetic fragment of the C-terminus of HGH (amino acids 176-191) that retains the fat-burning properties of growth hormone without affecting blood sugar or IGF-1 levels.
Mitochondrial Open Reading Frame of the 12S rRNA-c
A mitochondria-derived peptide that acts as a metabolic regulator, improving insulin sensitivity, exercise capacity, and potentially mimicking caloric restriction.